Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on October 4, 2021. The registrant is incorporated in California and is classified as an emerging growth company. The filing primarily addresses the appointment of a new executive officer and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The material event reported is the appointment of Gisela Paulsen as Chief Operating Officer, effective October 4, 2021. Key compensation details include:
- Base Salary: $390,000 annually.
- Target Bonus: 50% of annual base salary ($195,000), discretionary based on performance goals.
- Equity Grant: A one-time "sign-on" award of 375,000 stock options under the Oncocyte 2018 Equity Incentive Plan.
- Vesting Schedule: 25% vests after one year of continuous service; the remaining 75% vests in 36 equal monthly installments thereafter.
- Exercise Price: Fair market value of common stock on the grant date.
- Expiration: Options expire 10 years from the grant date.
Outlook, Risks, and Contingencies
Severance and Change in Control Provisions: A Change in Control and Executive Severance Plan Agreement was executed with Ms. Paulsen. Key contingencies include:
- Termination without Cause/Resignation for Good Reason (Standard): Entitles Ms. Paulsen to 12 months of base salary, pro-rated target bonus, 12 months of COBRA health benefits, and accelerated vesting of options scheduled to vest within 12 months of termination.
- Termination without Cause/Resignation for Good Reason (Near Change in Control): If termination occurs within 3 months prior to or 12 months following a change in control, Ms. Paulsen receives the standard benefits plus an additional 12 months of target cash bonus and full acceleration of all unvested stock options.
Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements are subject to risks and uncertainties detailed in the company's Form 10-K. The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the impact of the new COO's background (Exact Sciences, Roche, Genentech) on Oncocyte's strategic direction.
- Review the full text of the Severance Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Assess the dilution impact of the 375,000 stock option grant relative to the company's current outstanding share count.
- Confirm the fair market value of the stock on the grant date to determine the exercise price of the options.